바이오테크 보도자료
-
- FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treat...
- 2021년 10월 08일
-
- Fleet of Mobile Water Treatment Systems to Double by 2030 as Asian Companies Plans to Minimize Water Related Downtime: Fact.MR
- As per a study conducted by Fact.MR, the global mobile water treatment systems market is anticipated to surpass a valuation of US$ 3.62 Bn by 2030. Rising awareness about the benefits of water treatment and growing per capita income, especially in...
- 2021년 10월 08일
-
- SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
- SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda var...
- 2021년 10월 07일
-
- Takeda Provides Update on TAK-994 Clinical Program
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has sus...
- 2021년 10월 06일
-
- Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and JCR Pharmaceuticals Co., Ltd. (TSE:4552) (“JCR”) announced today a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafu...
- 2021년 10월 01일
-
- Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
- Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced final results of an analysis from five prospective trials of its investigational microbiota-based live biotherapeutic, RBX2660, for the reduction of recurrent C. difficile in...
- 2021년 09월 30일
-
- ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen® into Mainland China
- ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) to conduct cross-border sales of Tru Niagen® in mainland China. Sinopharm Xingsha is a subsidiary of Sinop...
- 2021년 09월 30일
-
- ANANDA Scientific and David Geffen School of Medicine UCLA Announce Clinical Trial Utilizing Liquid StructureTM Cannabidiol (CBD) for the Treatment of Opioid Use Disorder (OUD)
- ANANDA Scientific Inc., a biotech pharma company, today announced the commencement of a clinical trial to be done in collaboration with the Jane and Terry Semel Institute at David Geffen School of Medicine at UCLA, to evaluate Nantheia™ ATL5, an i...
- 2021년 09월 30일
-
- Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis
- Galderma today announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021. Results from tw...
- 2021년 09월 30일
-
- Zayed Sustainability Prize Announces 30 Finalists During Jury Meeting
- The Zayed Sustainability Prize, the UAE’s pioneering award for recognising sustainable solutions and humanitarianism, held its Jury meeting to elect winners for its current 2022 cycle, who will be announced during the Prize’s Awards Ceremony at th...
- 2021년 09월 30일
-
- MMIT/Evaluate Acquire Panalgo to Bring Speed and Trust to Pharma Analytics and Decision-Making
- Managed Markets Insight & Technology (MMIT) and Evaluate, (a Welsh, Carson, Anderson & Stowe and Hg portfolio company)—which joined forces last month to become a $1.6 billion global pharma commercial intelligence provider—announced the acquisition...
- 2021년 09월 29일
전시회
